Yahoo Finance • 7 hours ago
Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025A second Type C meetin... Full story
Yahoo Finance • 9 days ago
SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolu... Full story
Yahoo Finance • 29 days ago
MIAMI, July 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies comp... Full story
Yahoo Finance • 30 days ago
MIAMI, July 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 84th Emerging Growth Conference on July 16 & 17, 2025. The Emerging Growth Conference identifies comp... Full story
Yahoo Finance • last month
Clene Inc. (NASDAQ:CLNN), currently trading at $3.90 per share with a market capitalization of $35.48 million, announced Thursday that it has filed a prospectus supplement to offer and sell up to $2,015,000 of additional shares of its com... Full story
Yahoo Finance • last month
Investing.com - Clene Inc. (NASDAQ:CLNN), a $35.6 million market cap biotech company, has completed a Type-C meeting with the FDA regarding its CNM-Au8 treatment for amyotrophic lateral sclerosis (ALS), the company announced Tuesday. Acc... Full story
Yahoo Finance • last month
Investing.com - H.C. Wainwright has reiterated its Buy rating and $31.00 price target on Clene , Inc. (NASDAQ:CLNN), representing significant upside from the current price of $3.91. The bullish stance comes as the company updates its CNM-... Full story
Yahoo Finance • 3 months ago
MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies compan... Full story
Yahoo Finance • 3 months ago
MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies compan... Full story
Yahoo Finance • 4 months ago
SALT LAKE CITY, April 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to advancin... Full story
Yahoo Finance • 5 months ago
SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases... Full story
Yahoo Finance • 5 months ago
SALT LAKE CITY, March 06, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revol... Full story
Yahoo Finance • 2 years ago
Clene Inc. Journal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy metabolites in multiple sclerosis and Parkinson’s disease with CNM-Au8® treatm... Full story
Yahoo Finance • 2 years ago
LOS ANGELES, CA - (NewMediaWire) - December 12, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company. Clene (NASDAQ: CLNN), together with its w... Full story
Yahoo Finance • 2 years ago
LOS ANGELES, CA - (NewMediaWire) - November 14, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company. Clene, a company targeting the treatment... Full story
Yahoo Finance • 2 years ago
Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8® in the RESCUE ALS open-label extension trialReported statistically significant long-... Full story
Yahoo Finance • 2 years ago
SALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totali... Full story
Yahoo Finance • 2 years ago
Novel catalytic mechanism of CNM-Au8 reveals its promise as a versatile new treatment to address multiple assaults on neuronal health in neurodegenerative diseases SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: C... Full story
Yahoo Finance • 2 years ago
SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on impro... Full story
Yahoo Finance • 2 years ago
Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8® 30mg compared to PRO-ACT matched placebo over long-term follow-up, p=0.046Prolonged life with 59% decreased risk of dea... Full story